Oral ganciclovir for treatment of cytomegalovirus viremia in patients receiving allogeneic stem cell transplantation
- VernacularTitle:更昔洛韦胶囊在造血干细胞移植患者巨细胞病毒血症中的应用
- Author:
Yu WANG
;
Xiaojun HUANG
;
Lanping XU
- Publication Type:Journal Article
- Keywords:
Ganciclovir;
Cytomegalovirus;
Stem cell transplantation
- From:
Chinese Journal of Practical Internal Medicine
2006;0(23):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of oral ganciclovir on cytomegalovirus viremia in patients receiving allogeneic stem cell transplantation.Methods Thirty patients who were treated with oral ganciclovir from Feb,2006 to May,2006 were studied.Intravenous ganciclovir was used 10 mg/(kg?d)for eight days before HSCT as prophylaxis of CMV infection.Cytomegalovirus was detected after HSCT once a week using polymerase chain reaction(PCR)method.If CMV was positive and CMV-DNA load was higher than 6.0?102 copies/mL and lower than 105 copies/mL,oral ganciclovir was used for the treatment(1 g,three times a day).Results CMV viremia was positive at a median time of 42 days after HSCT;median CMV-DNA load was 4.626?103 copies/mL.Good response on CMV DNA load(reduction below 6.0?102 copies/mL)was observed in 90% of oral ganciclovir and the response rate was 70.0% within 14 days.Median duration of therapy for good response was 10 days(range 2~30 days).Severe adverse effects were not observed and CMV-related disease did not occur.Conclusion Oral ganciclovir is an attractive and safe alternative for pre-emptive CMV viremia treatment in allo-HSCT recipients.
